Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

Xiaowei Wu is a Principal Investigator of Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Zhongshan Institute for Drug Discovery, the Institutes of Drug Discovery and Development, CAS. He obtained his PhD degree in 2017 from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), China. From 2017 to 2021, He worked as a post-doc at H. Lee Moffitt Cancer Center & Research Institute and Baylor College of Medicine, respectively. Dr. Wu’s primary interest is the development of novel small-molecule therapeutics for the treatment of cancer and other diseases.

Education

2008.9-2012.6 B.S. in Pharmacy, Sichuan University

2012.9-2017.6 Ph.D in Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Work Experience

2017.8-2018.6 Postdoctoral fellow, Department of Drug Discovery, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA

2018.6-2021.02 Postdoctoral fellow, Department of Pharmacology and Chemical Biology, Baylor College of Medicine, Houston, Texas, USA

Research Directions

Medicinal chemistry, the development of transition-metal-catalyzed reactions and their application in the medicinal chemistry

Grants & Research Projects

Achievements

1. Design and synthesis of covalent FGFR inhibitors, which showed a highly selective and potent FGFR inhibition profile.

2. An efficient Ru(II)-catalyzed redox-neutral [4 + 1] annulation of benzamides and propargyl alcohols by C？H bond activation for accessing potentially bioactive N-substituted quaternary isoindolinones was developed, in which propargyl alcohols serve as rare one-carbon components.

3. A ruthenium(II)-catalyzed C？H allylation at the C-2 position of N-ethoxycarbamoyl indoles with allyl alcohols via β-hydroxide elimination was developed. Further, this method does not require high temperature, external oxidants, and expensive additives. This work was highlighted by Synfacts and ChemistryViews.

morefold

Social Titles

morefold

Awards & Honors

2017 Outstanding Graduate Award of Shanghai

morefold

Pubilcations

Full Publication List

Selected Publications

1.Xiaowei Wu, Bao Wang, Shengbin Zhou, Yu Zhou, Hong Liu. Ruthenium-Catalyzed Redox-Neutral [4+1] Annulation of Benzamides and Propargyl alcohols via C-H Bond Activation. ACS Catalysis, 2017, 7, 2494-2499.

2.Xiaowei Wu, Bao Wang, Yu Zhou, Hong Liu. Propargyl alcohols as one-carbon synthons: redox-neutral Rh (III)-catalyzed C-H bond activation for the synthesis of isoindolinones bearing a quaternary carbon. Organic Letters, 2017, 19, 1294-1297.

3.Xiaowei Wu, Haitao Ji. Ruthenium(II)-Catalyzed Regio- and Stereoselective C？H Allylation of Indoles with Allyl Alcohols. Organic Letters, 2018, 20, 2224-2227. Highlighted by Synfacts and ChemistryViews.

4.Xiaowei Wu, Yangbin Lu, Jin Qiao, Wenhao Dai, Xiuwen Jia, Hangcheng Ni, Xiaoning Zhang, Hong Liu, and Fei Zhao. Rhodium(III)-Catalyzed C–H Alkenylation/Directing Group Migration for the Regio- and Stereoselective Synthesis of Tetrasubstituted Alkenes. Organic Letters, 2020, 22, 9163-9168.

5.Xiaowei Wu, Dengyou Zhang, Shengbin Zhou, Feng Gao, Hong Liu. Site-specific indolation of proline-based peptides via copper(II)-catalyzed oxidative coupling of tertiary amine N-oxides. Chemical Communications, 2015, 51, 12571-12573.

6.Xiaowei Wu, Mengdi Dai, Jihui Zhao, Yulan Wang, Chunpu Li, Xia Peng, Rongrong Cui, Bao Wang, Yang Dai, Dan Feng, Hualiang Jiang, Meiyu Geng, Jing Ai, Mingyue Zheng, Hong Liu. Design, Synthesis and pharmacological evaluation of pyrazolo[3,4-d]pyridazinone derivatives as covalent FGFR inhibitors. Acta Pharmaceutica Sinica B. 2021, 11, 781-794.

7.Yulan Wang,# Yang Dai,# Xiaowei Wu (共同一作),# Fei Li, Bo Liu, Chunpu Li, Qiufeng Liu, Yuanyang Zhou, Bao Wang, Mingrui Zhu, Rongrong Cui, Xiaoqin Tan, Zhaoping Xiong, Jia Liu, Minjia Tan, Yechun Xu, Mei-Yu Geng, Hualiang Jiang, Hong Liu, Jing Ai, Mingyue Zheng. The Discovery and Development of a Series of Pyrazolo[3,4-d]pyridazinone Compounds as Novel Covalent FGFR Inhibitors by Rational Drug Design. J. Med. Chem. 2019, 62, 7473-7488.

8.Fei Zhao,* Xin Gong, Yangbin Lu, Jin Qiao, Xiuwen Jia, Hangcheng Ni, Xiaowei Wu (共同通讯),* Xiaoning Zhang*. Additive-Controlled Divergent Synthesis of Tetrasubstituted 1,3-Enynes and Alkynylated 3H-pyrrolo[1,2-a]indol-3-ones via Rhodium Catalysis. Organic Letters, 2021, 23, 727-733.

morefold